296 related articles for article (PubMed ID: 8059289)
1. [Retrospective analysis of hemotherapy support in 226 cases of myelodysplastic syndromes].
Rubio-Félix D; Franco E; Giraldo P; Gimeno J; Cuesta I; Giralt M
Sangre (Barc); 1994 Apr; 39(2):117-20. PubMed ID: 8059289
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems.
Rubio-Felix D; Giraldo P; Franco E; Gimeno J; Giralt M
Hematol Oncol; 1995; 13(3):139-52. PubMed ID: 7622144
[TBL] [Abstract][Full Text] [Related]
4. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic factors in myelodysplastic syndromes: analysis of 72 cases].
Krieger O; Bernhart M; Desser H; Nowotny H; Lutz D
Wien Klin Wochenschr; 1985 Feb; 97(3):131-6. PubMed ID: 3984346
[TBL] [Abstract][Full Text] [Related]
6. [Prediction of survival in myelodysplastic syndrome. Analysis of 2 scoring systems with prognostic value].
Sanz GF; Sanz MA; Vallespí T; Cañizo MC; García S; Torrabadella M; San Miguel JF; Irriguible D
Sangre (Barc); 1989 Feb; 34(1):41-6. PubMed ID: 2711284
[TBL] [Abstract][Full Text] [Related]
7. [Chromosome abnormalities in myelodysplastic syndrome].
Fujita K; Mori H; Niikura H; Terada H; Shinohara T
Rinsho Byori; 1990 Aug; 38(8):911-6. PubMed ID: 2232253
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes in patients under 50 years old: a single institution experience.
Breccia M; Mengarelli A; Mancini M; Biondo F; Gentilini F; Latagliata R; Mandelli F; Alimena G
Leuk Res; 2005 Jul; 29(7):749-54. PubMed ID: 15927670
[TBL] [Abstract][Full Text] [Related]
9. A study of the haematologic spectrum of myelodysplastic syndrome.
Kini J; Khadilkar UN; Dayal JP
Indian J Pathol Microbiol; 2001 Jan; 44(1):9-12. PubMed ID: 12561987
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide for the treatment of patients with myelodysplastic syndromes.
Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
[TBL] [Abstract][Full Text] [Related]
11. [Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients].
Dewulf G; Gouin I; Pautas E; Gaussem P; Chaïbi P; Andreux JP; Siguret V
Ann Biol Clin (Paris); 2004; 62(2):197-202. PubMed ID: 15047472
[TBL] [Abstract][Full Text] [Related]
12. [Evolutive epidemiologic profile of myelodysplastic syndromes (1959-1993). Comparative study with acute myeloid leukemia and aplastic pancytopenias].
Sánchez Fayos J; Outeiriño Pérez JJ; Prieto E; Román A; Olavarría E; Cabello A; Soto C; Calabuig T; Paniagua C; Sanz B
Sangre (Barc); 1994 Dec; 39(6):441-8. PubMed ID: 7855696
[TBL] [Abstract][Full Text] [Related]
13. [Study on pathophysiology of the myelodysplastic syndromes (MDS)--pattern of dysmegakaryopoiesis related to leukemic transformation].
Tomonaga M; Jinnai I; Kuriyama K; Nonaka H; Amenomori T; Matsuo T; Yoshida Y; Sasagawa I; Sadamori N; Ichimaru M
Rinsho Ketsueki; 1989 Oct; 30(10):1788-99. PubMed ID: 2593245
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of c-myc p67 oncoprotein in patients with myelodysplastic syndromes in transformation to acute leukaemia.
Kyriakou D; Eliopoulos AG; Alexandrakis M; Kalokyri I; Eliopoulos GD
Haematologia (Budap); 1996; 28(1):1-7. PubMed ID: 9283897
[TBL] [Abstract][Full Text] [Related]
15. [An analysis of prognostic factors in 80 myelodysplastic syndrome].
Xu XQ; Wang JM; Lu SQ; Chen L; Yang JM; Zhang WP; Song XM; Xu YQ; Gong SL; Hou J; Ni X
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):723-7. PubMed ID: 19176004
[TBL] [Abstract][Full Text] [Related]
16. Levels of soluble forms of ICAM and VCAM in patients with myelodysplastic syndromes and their prognostic significance.
Passam FH; Tsirakis G; Boula A; Fragou A; Consolas I; Alegakis A; Kyriakou DS; Alexandrakis MG
Clin Lab Haematol; 2004 Dec; 26(6):391-5. PubMed ID: 15595996
[TBL] [Abstract][Full Text] [Related]
17. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
18. [Myelodysplastic syndrome--classification, prognosis and therapy].
Cermák J; Michalová K; Vítek A
Cas Lek Cesk; 2002 Sep; 141 Suppl():33-7. PubMed ID: 12428420
[TBL] [Abstract][Full Text] [Related]
19. [Culture of cells forming granulomonocytic colonies in bone marrow (GM-CFU) in myelodysplastic syndromes and their relation to hematological findings and FAB subtype].
García M; Sanz GF; Arriaga F; Pérez-Sirvent ML; Marty ML; Sanz MA
Sangre (Barc); 1991 Aug; 36(4):269-75. PubMed ID: 1776105
[TBL] [Abstract][Full Text] [Related]
20. [Myelodysplasias: clinical experience with 35 patients].
Chuecas F; Grebe G; Jalil R; Lira P
Rev Med Chil; 1990 Nov; 118(11):1211-7. PubMed ID: 2152645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
